The stock of Uniqure NV (NASDAQ:QURE) reached all time low today, Oct, 28 and still has $5.95 target or 14.00% below today’s $6.92 share price. This indicates more downside for the $166.38 million company. This technical setup was reported by Barchart.com. If the $5.95 PT is reached, the company will be worth $23.29M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 147,700 shares traded hands. Uniqure NV (NASDAQ:QURE) has declined 41.03% since March 28, 2016 and is downtrending. It has underperformed by 45.74% the S&P500.
Uniqure NV (NASDAQ:QURE) Ratings Coverage
Out of 9 analysts covering uniQure N.V. (NASDAQ:QURE), 9 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. uniQure N.V. has been the topic of 18 analyst reports since August 7, 2015 according to StockzIntelligence Inc. On Monday, November 30 the stock rating was reinitiated by Roth Capital with “Buy”. The rating was maintained by WallachBeth Capital on Tuesday, December 1 with “Buy”. Roth Capital maintained the shares of QURE in a report on Monday, September 21 with “Buy” rating. On Wednesday, June 15 the stock rating was maintained by WallachBeth Capital with “Buy”. The stock has “Outperform” rating given by Leerink Swann on Tuesday, September 22. The firm earned “Buy” rating on Thursday, August 27 by Chardan Capital Markets. Piper Jaffray maintained Uniqure NV (NASDAQ:QURE) on Monday, September 21 with “Buy” rating. The rating was initiated by Janney Capital with “Buy” on Tuesday, December 1. The firm has “Buy” rating by Zacks given on Tuesday, September 1. The company was maintained on Friday, August 28 by WallachBeth Capital.
According to Zacks Investment Research, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.”
More news for Uniqure NV (NASDAQ:QURE) were recently published by: Fool.com, which released: “Why uniQure NV Stock Skyrocketed Today” on April 06, 2015. Marketwatch.com‘s article titled: “/quotes/zigman/3870025/realtime” and published on February 05, 2014 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.